OLAIDE AKINYINKA: Open Payments
NPI 1932637097 · KATY, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,015 in 38 payments from 10 companies in 2025. Trend: 2023 $1,344 · 2024 $1,309 · 2025 $1,015
Food & beverage: $1,015
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $179 |
| ABBVIE INC. | 13 | $174 |
| Alkermes, Inc. | 5 | $170 |
| Axsome Therapeutics, Inc. | 4 | $147 |
| Otsuka America Pharmaceutical, Inc. | 4 | $92 |
| Teva Pharmaceuticals USA, Inc. | 1 | $84 |
| Neurocrine BioSciences, Inc. | 2 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $53 |
| Bausch Health US, LLC | 2 | $32 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
Products named: CAPLYTA, VRAYLAR, Auvelity, LYBALVI, ARISTADA, AUSTEDO XR, REXULTI, INGREZZA.
Industry payments across TX — which companies pay providers there.
